Tipperary-based Amneal Pharmaceuticals has officially launched its first two products on the US commercial market, with both metered-dose inhalation products manufactured at the company's Cashel facility, marking a significant step forward for the pharmaceutical company and the wider Tipperary regional economy, according to the Irish Independent.

The two products, Albuterol Sulfate Inhalation Aerosol and Beclomethasone Dipropionate HFA Inhalation Aerosol, represent Amneal's first metered-dose inhalation products introduced to the US market. Albuterol is indicated for the treatment and prevention of bronchospasm and exercise-induced bronchospasm, while beclomethasone is a corticosteroid used for the maintenance treatment of asthma.

Local Fine Gael councillor Declan Burgess welcomed the commercial launch, describing it as a major step forward for both the company and the region.

Cllr Burgess said: "Amneal has been a fantastic contributor to economic activity in both Cashel and across county Tipperary. Their recent transition into the commercial market marks a major step forward and represents a significant boost for the local economy."

The Cashel facility's transition into commercial-scale production positions Amneal as a contributor to Ireland's growing reputation as a manufacturing base for complex pharmaceutical dosage forms, including specialised inhalation therapies destined for major global markets.

Metered-dose inhalation products represent a technically demanding segment of pharmaceutical manufacturing, requiring stringent quality controls and regulatory compliance for market access in the United States.

The commercial launch reinforces the strategic importance of Amneal's Tipperary operations within its broader global manufacturing network.

Read the complete report for further detail on Amneal's commercial market entry and Tipperary operations.